Cargando…
AmyP53, a Therapeutic Peptide Candidate for the Treatment of Alzheimer’s and Parkinson’s Disease: Safety, Stability, Pharmacokinetics Parameters and Nose-to Brain Delivery
Neurodegenerative disorders are a major public health issue. Despite decades of research efforts, we are still seeking an efficient cure for these pathologies. The initial paradigm of large aggregates of amyloid proteins (amyloid plaques, Lewis bodies) as the root cause of Alzheimer’s and Parkinson’...
Autores principales: | Di Scala, Coralie, Armstrong, Nicholas, Chahinian, Henri, Chabrière, Eric, Fantini, Jacques, Yahi, Nouara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654333/ https://www.ncbi.nlm.nih.gov/pubmed/36362170 http://dx.doi.org/10.3390/ijms232113383 |
Ejemplares similares
-
AmyP53 Prevents the Formation of Neurotoxic β-Amyloid Oligomers through an Unprecedent Mechanism of Interaction with Gangliosides: Insights for Alzheimer’s Disease Therapy
por: Azzaz, Fodil, et al.
Publicado: (2023) -
Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection
por: Fantini, Jacques, et al.
Publicado: (2020) -
Gene Therapy Strategy for Alzheimer’s and Parkinson’s Diseases Aimed at Preventing the Formation of Neurotoxic Oligomers in SH-SY5Y Cells
por: El-Battari, Assou, et al.
Publicado: (2021) -
Anandamide Revisited: How Cholesterol and Ceramides Control Receptor-Dependent and Receptor-Independent Signal Transmission Pathways of a Lipid Neurotransmitter
por: Scala, Coralie Di, et al.
Publicado: (2018) -
Common molecular mechanism of amyloid pore formation by Alzheimer’s β-amyloid peptide and α-synuclein
por: Di Scala, Coralie, et al.
Publicado: (2016)